Gene synthesis companies establish measures to counter bioterrorism
By European Biotechnology Science and Industry News,
European Biotechnology Science and Industry News
| 11. 20. 2009
The five largest suppliers of synthetic DNA will establish common measures to prevent misuse of synthetically produced DNA by bioterorrists or criminals. Yesterday, Blue Heron Biotechnology, DNA2.0, GENEART, GenScript and Integrated DNA Technologies, which together represent an 80% share of the synthetic DNA market, announced the establishment of a common screening protocol that will be applied to every single synthetic gene order. "We are proud to announce the formation of the International Gene Synthesis Consortium", said John Mulligan, CSO of Blue Heron Biotechnology.
The IGSC's "Harmonized Screening Protocol" is comprised of the screening of gene sequences against a regulated pathogen database developed by the consortium and one or more of the internationally coordinated sequence reference databanks, such as NCBI/GenBank, EBI/EMBL, or DDBJ. Amino acid sequences of possible translation products for each ordered synthetic gene will also be screened. Purchasers of synthetic genes will also be screened in accordance with national guidelines. Furthermore, the IGSC companies have agreed to keep all screening, customer, and order records for at least eight years. IGSC companies have also reserved the right to refuse to...
Related Articles
By Alondra Nelson, Science | 01.15.2026
One of the most interventionist approaches to technology governance in the United States in a generation has cloaked itself in the language of deregulation. In early December 2025, President Donald Trump took to Truth Social to announce a forthcoming “One...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...